id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303192-il3s8lgp	Tam, Lai‐Shan	Care for patients with rheumatic diseases during COVID‐19 pandemic: A position statement from APLAR	2020-05-27		.txt	text/plain	1794	95	39	Patients with rheumatic diseases are at higher risk of respiratory infections including influenza and pneumococcal pneumonia, which is attributed to the underlying disease, comorbidities and immunosuppressive therapy, 1 but to date we lack good information about the virus SARS-CoV-2. In the desperate search to find effective treatments for COVID-19, drugs largely used by rheumatologists have entered the spotlight, including the caution against use of non-steroidal anti-inflammatory drugs (NSAIDs), the potential of antimalarials and biologic disease-modifying anti-rheumatic drugs (bDMARDs), for example anti-interleukin-6 (IL-6) and targeted synthetic DMARDS (tsDMARDs) Janus-activated kinase (JAK) inhibitors to manage cytokine storm syndrome (CSS)/cytokine release syndrome associated with COVID-19. 18 In order to gather real-world data to inform treatment strategies and better characterize individuals at increased risk of infection, the COVID-19 Global Rheumatology Alliance has successfully dePreclinical and limited clinical data suggested that hydroxychloroquine (HCQ) and chloroquine (CLQ) have antiviral activities against SARS-CoV-2.	./cache/cord-303192-il3s8lgp.txt	./txt/cord-303192-il3s8lgp.txt